Research Article

Evaluation of Feed Strategy for High Quality Biosimilar IgG Production in CHO Cell Fed-batch Process

Volume: 13 Number: 1 January 1, 2022
EN

Evaluation of Feed Strategy for High Quality Biosimilar IgG Production in CHO Cell Fed-batch Process

Abstract

Purpose: Chinese Hamster Ovary (CHO) cells are currently the leading hosts for biosimilar Immunoglobulin G (IgG) production in the biopharmaceutical industry. Most eukaryotic proteins are glycosylated, and charge variants affect both the in vivo and in vitro properties of monoclonal antibodies (mAb). Adjusting the N-glycosylation patterns and charge variants while achieving high antibody titer is a production challenge. In this study, the effects of feed type and strategy on cell growth, product titer, glycosylation and charge variation were investigated using different CHO clones producing different IgG mAbs. Methods: Cultivated CHO cells were supplemented with different feeding schemes, under fed-batch productions of 14 days. Screenings were conducted in spin-tubes and further investigated in 3L bioreactor systems. Results: Change in feed strategy decreased productivities by 10.4% (P < 0.05), while it increased non-fucosylated glycoforms by 33.3% and enhanced galactosylation up to 3-folds. Basic variants were observed to increase 2.5 folds. Conclusion: These remarkable alterations are of great importance in terms of mAb quality, in a manufacturing point of view, as they provide modulation of efficacy and safety. This reveals that feed strategy is a major driving force that significantly impacts culture longevity, galactosylated glycoforms, high-mannose glycan contents and charge variants.

Keywords

References

  1. Reference1. Del Val IJ, Kontoravdi C, Nagy JM. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns. Biotechnol Prog 2010; 26(6):1505–27.
  2. Reference2. Boune S, Hu P, Epstein AL, Khawli LA. Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations. Antibodies 2020; 9(2):22.
  3. Reference3. Pacis E, Yu M, Autsen J, Bayer R, Li F. Effects of cell culture conditions on antibody N-linked glycosylation-what affects high mannose 5 glycoform. Biotechnol Bioeng 2011; 108(10):2348–58.
  4. Reference4. Wong DCF, Wong NSC, Goh JSY, May LM, Yap MGS. Profiling of N-glycosylation gene expression in CHO cell fed-batch cultures. Biotechnol Bioeng 2010; 107(3):516–28.
  5. Reference5. Kochanowski N, Blanchard F, Cacan R, Chirat F, Guedon E, Marc A, et al. Influence of intracellular nucleotide and nucleotide sugar contents on recombinant interferon-γ glycosylation during batch and fed-batch cultures of CHO cells. Biotechnol Bioeng 2008; 100(4):721–33.
  6. Reference6. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs 2010; 2(6):613–24.
  7. Reference7. Takagi Y, Kikuchi T, Wada R, Omasa T. The enhancement of antibody concentration and achievement of high cell density CHO cell cultivation by adding nucleoside. Cytotechnology 2017; 69(3):511–21.
  8. Reference8. Xu J, Rehmann MS, Xu X, Huang C, Tian J, Qian NX, et al. Improving titer while maintaining quality of final formulated drug substance via optimization of CHO cell culture conditions in low-iron chemically defined media. MAbs 2018; 10(3):488–99.

Details

Primary Language

English

Subjects

Microbiology

Journal Section

Research Article

Publication Date

January 1, 2022

Submission Date

May 7, 2021

Acceptance Date

November 10, 2021

Published in Issue

Year 2022 Volume: 13 Number: 1

EndNote
Ayyıldız Tamis D, Ustuner B, Dayankac Unver S, Turgut T, Baycın D (January 1, 2022) Evaluation of Feed Strategy for High Quality Biosimilar IgG Production in CHO Cell Fed-batch Process. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 13 1 6–15.